Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

NASDAQ:APRE

Aprea Therapeutics, Inc.

Last Close

3.81

26/07 20:00

Market Cap

21.45M

Beta: -

Volume Today

3.70K

Avg: 15.86K

PE Ratio

−0.19

PFCF: −1.88